Bone marrow suppression and anemia are frequent side effects of treatment of the acquired immunodeficiency syndrome (AIDS) with zidovudine (formerly azidothymidine [AZT]). We conducted a randomized, double-blind, placebo-controlled clinical trial of recombinant human erythropoietin (100 U per kilogram of body weight thrice weekly by intravenous bolus) in 63 patients with AIDS treated with zidovudine (29 in the erythropoietin group and 34 in the placebo group). Reductions in the number of units of red cells transfused and the number of patients given transfusions per month became apparent in the second and third months of the trial. The reductions were observed in patients with endogenous erythropoietin levels less than or equal to 500 IU per liter at base line, but not in patients whose levels were greater than 500 IU per liter at the beginning of the study. Although the hematocrit and hemoglobin level were not used as the primary criteria of efficacy because the patients received transfusions when their physicians decided that they needed them, a significantly higher rate of increase in the hematocrit was observed in the patients treated with recombinant human erythropoietin whose levels of endogenous erythropoietin were less than or equal to 500 IU per liter (0.00353 points per week) than in the patients given placebo (0.00116 points per week). This effect was not seen in patients with higher levels of endogenous erythropoietin. Serious side effects did not occur more often in the group treated with erythropoietin than in the placebo group. We conclude that recombinant human erythropoietin may be useful in patients with AIDS treated with zidovudine, although the indicators for its use remain to be clarified.
Source Information
University of Miami, Fla.
This article has been cited by other articles:
Henry, D. H., Bowers, P., Romano, M. T., Provenzano, R.
(2004). Epoetin Alfa: Clinical Evolution of a Pleiotropic Cytokine. Arch Intern Med
164: 262-276
[Abstract][Full Text]
Fisher, J. W.
(2003). Erythropoietin: Physiology and Pharmacology Update. Exp. Biol. Med.
228: 1-14
[Abstract][Full Text]
Schett, G., Firbas, U., Fureder, W., Hiesberger, H., Winkler, S., Wachauer, D., Koller, M., Kapiotis, S., Smolen, J.
(2001). Decreased serum erythropoietin and its relation to anti-erythropoietin antibodies in anaemia of systemic lupus erythematosus. Rheumatology (Oxford)
40: 424-431
[Abstract][Full Text]
Bogden, J. D, Kemp, F. W, Han, S., Li, W., Bruening, K., Denny, T., Oleske, J. M, Lloyd, J., Baker, H., Perez, G., Kloser, P., Skurnick, J., Louria, D. B
(2000). Status of selected nutrients and progression of human immunodeficiency virus type 1 infection. Am. J. Clin. Nutr.
72: 809-815
[Abstract][Full Text]
Ebert, B. L., Bunn, H. F.
(1999). Regulation of the Erythropoietin Gene. Blood
94: 1864-1877
[Full Text]
BROCHU, E., LACASSE-M, S., LARIVIÈRE, R., KINGMA, I., GROSE, J. H., LEBEL, M.
(1999). Differential Effects of Endothelin-1 Antagonists on Erythropoietin-Induced Hypertension in Renal Failure. J. Am. Soc. Nephrol.
10: 1440-1446
[Abstract][Full Text]
D'Ambra, M. N., Gray, R. J., Hillman, R., Jones, J. W., Kim, H. C., Rawitscher, R., Schnaper, H., Szymanski, I., Vlahakes, G. J., Kaplan, D., Lynch, K. E., Guilfoyle, M., Abels, R. I.
(1997). Effect of Recombinant Human Erythropoietin on Transfusion Risk in Coronary Bypass Patients. Ann. Thorac. Surg.
64: 1686-1693
[Abstract][Full Text]
Cazzola, M., Mercuriali, F., Brugnara, C.
(1997). Use of Recombinant Human Erythropoietin Outside the Setting of Uremia. Blood
89: 4248-4267
[Full Text]
Abels, R. I., Larholt, K. M., Krantz, K. D., Bryant, E. C.
(1996). Recombinant Human Erythropoietin (rHuEPO) for the Treatment of the Anemia of Cancer. The Oncologist
1: 140-150
[Abstract][Full Text]
Heller, H. M., Dzieczkowski, J. S.
(1993). Case 36-1993- A 28-Year-Old Man with AIDS, Persistent Pancytopenia, and Lymphoma. NEJM
329: 792-799
[Full Text]
Matsumoto, S. A., Seideman, M. F.
(1992). Considerations in the Treatment of Patients With Acquired Immunodeficiency Syndrome at Home. Journal of Pharmacy Practice
5: 158-163
[Abstract]
Mitsuya, H, Yarchoan, R, Broder, S
(1990). Molecular targets for AIDS therapy. Science
249: 1533-1544
[Abstract]
Previous
